D.A. Davidson & CO. Cuts Position in Gilead Sciences, Inc. $GILD

D.A. Davidson & CO. decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.6% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 72,419 shares of the biopharmaceutical company’s stock after selling 5,090 shares during the quarter. D.A. Davidson & CO.’s holdings in Gilead Sciences were worth $9,149,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Vest Financial LLC grew its holdings in Gilead Sciences by 0.7% in the second quarter. Vest Financial LLC now owns 24,740 shares of the biopharmaceutical company’s stock valued at $3,126,000 after purchasing an additional 163 shares during the period. Beta Wealth Group Inc. lifted its position in shares of Gilead Sciences by 5.4% during the 2nd quarter. Beta Wealth Group Inc. now owns 5,924 shares of the biopharmaceutical company’s stock valued at $748,000 after buying an additional 302 shares in the last quarter. Nicholas Wealth LLC. lifted its position in shares of Gilead Sciences by 4.3% during the 2nd quarter. Nicholas Wealth LLC. now owns 8,912 shares of the biopharmaceutical company’s stock valued at $1,126,000 after buying an additional 366 shares in the last quarter. Signaturefd LLC grew its stake in Gilead Sciences by 0.6% in the 2nd quarter. Signaturefd LLC now owns 25,292 shares of the biopharmaceutical company’s stock valued at $3,195,000 after acquiring an additional 154 shares during the period. Finally, Crewe Advisors LLC grew its stake in Gilead Sciences by 32.1% in the 2nd quarter. Crewe Advisors LLC now owns 1,032 shares of the biopharmaceutical company’s stock valued at $130,000 after acquiring an additional 251 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the sale, the chief financial officer owned 171,646 shares in the company, valued at approximately $21,524,408.40. This represents a 1.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the completion of the transaction, the chief executive officer directly owned 592,133 shares in the company, valued at $77,160,851.23. This trade represents a 2.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 51,000 shares of company stock worth $6,568,860. Insiders own 0.30% of the company’s stock.

Gilead Sciences Trading Up 0.2%

Shares of GILD stock opened at $138.36 on Friday. Gilead Sciences, Inc. has a fifty-two week low of $108.46 and a fifty-two week high of $157.29. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The stock’s fifty day moving average is $130.11 and its two-hundred day moving average is $136.45. The firm has a market capitalization of $171.56 billion, a P/E ratio of -51.82 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. The business had revenue of $7.80 billion during the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The company’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.01 earnings per share. Research analysts expect that Gilead Sciences, Inc. will post -0.53 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio is currently -122.85%.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Appeals court ruling protects Gilead’s distribution channels. A U.S. appeals court upheld an injunction preventing alternative funding programs and related businesses from importing Gilead medications overseas. The decision could reduce the size of the alternative funding industry and help protect Gilead’s pricing, sales channels and patient-assistance economics. Court rules companies can’t import Gilead medications from overseas in blow to AFP health programs
• Positive Sentiment: Q2 growth highlighted continued commercial momentum. Gilead’s HIV franchise led year-over-year sales growth, with Biktarvy and PrEP performing particularly well. Quarterly PrEP sales reportedly doubled to more than $1 billion, while Trodelvy, Livdelzi and progress in oncology and liver disease added to the growth outlook. 5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call
• Positive Sentiment: AI collaboration strengthens the oncology pipeline. Gilead partnered with Nucleai to use AI-powered tissue analytics in its antibody-drug-conjugate programs. The technology is intended to accelerate biomarker discovery and improve precision-oncology development. Gilead Sciences Expands ADC Research With AI Tissue Analytics
• Positive Sentiment: Merck partnership offers longer-term growth potential. Recent clinical and regulatory progress involving Gilead and Merck’s collaboration reinforces the possibility that the partnership could produce meaningful future growth in areas such as oncology and infectious disease. Could Merck and Gilead’s Partnership Create the Next Big Pharma Growth Engine
• Neutral Sentiment: Analysts and investors continue to debate whether Gilead remains attractively valued after its strong multiyear performance. High call-option activity signals bullish positioning but does not guarantee sustained gains.
• Negative Sentiment: An analyst reduced the FY2026 EPS forecast, potentially reflecting concerns about earnings normalization, expenses or pipeline investment. The revision may limit near-term upside despite Gilead’s solid revenue trends. FY2026 EPS Forecast for Gilead Sciences Reduced by Analyst

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on GILD shares. Needham & Company LLC restated a “buy” rating and set a $170.00 price objective on shares of Gilead Sciences in a research report on Wednesday, August 5th. Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price on the stock in a research report on Wednesday, May 20th. HSBC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and boosted their target price for the stock from $133.00 to $155.00 in a research note on Monday, July 6th. Daiwa Securities Group reduced their price target on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research report on Tuesday, May 19th. Finally, Truist Financial lowered their price objective on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a report on Tuesday, July 7th. Twenty-four equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $158.04.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.